| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017550 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017551 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017552 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017553 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017554 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017555 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017556 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017557 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10017558 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
| TVIS10015644 | HBV | ENSG00000138115.15 | protein_coding | CYP2C8 | No | No | 1558 | B7Z1F5 P10632 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CYP2C8 |
|---|---|
| DrugBank ID | DB03796 |
| Drug Name | Palmitic Acid |
| Target ID | BE0002887 |
| UniProt ID | P10632 |
| Regulation Type | |
| PubMed IDs | 14676196 |
| Citations | Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF: Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem. 2004 Mar 5;279(10):9497-503. Epub 2003 Dec 15. |
| Groups | Approved |
| Direct Classification | Long-chain fatty acids |
| SMILES | CCCCCCCCCCCCCCCC(O)=O |
| Pathways | Cerivastatin Action Pathway; Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD); Ethylmalonic Encephalopathy; Familial Hypercholanemia (FHCA); Desmosterolosis; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Congenital Bile Acid Synthesis Defect Type III; Glycerolipid Metabolism; Ibandronate Action Pathway; Cerebrotendinous Xanthomatosis (CTX); Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2); Smith-Lemli-Opitz Syndrome (SLOS); Carnitine Palmitoyl Transferase Deficiency II; Hyper-IgD Syndrome; Zellweger Syndrome; Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD); Steroid Biosynthesis; Hypercholesterolemia; Risedronate Action Pathway; Mevalonic Aciduria; Glutaric Aciduria Type I; Alendronate Action Pathway; CHILD Syndrome; D-Glyceric Acidura; Lovastatin Action Pathway; Wolman Disease; Bile Acid Biosynthesis; Long Chain Acyl-CoA Dehydrogenase Deficiency (LCAD); Glycerol Kinase Deficiency; Atorvastatin Action Pathway |
| PharmGKB | |
| ChEMBL | CHEMBL82293 |
